Boehringer Ingelheim's Zongertinib Trial Targets Advanced Cancers with HER2 Alterations
Boehringer Ingelheim is conducting a trial (PANTUMOR-1) to evaluate zongertinib in patients with advanced cancers harboring HER2 alterations.
Therapeutic Area
Therapeutic area intelligence for HER2 Alterations with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.